Triple Negative Breast Cancer Market Size Worth USD 1,463.82 Million by 2030

Data Bridge Market Research analyses a growth rate in the global triple-negative breast cancer market in 2023-2030. The expected CAGR of the global triple negative breast cancer market is around 5.50% in the mentioned forecast period. The market was valued at USD 953.8 million in 2022 and would grow to USD 1,463.82 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-triple-negative-breast-cancer-market

Breast cancer is the second most prevalent cancer in the world and is the most common cancer in women worldwide. Mostly metastatic breast cancer may be detected months or years after the advanced or early detection and treatment of breast cancer, such as stages 1, 2, or 3. Current advancements in cancer research continue to lead to the launch of newer and better treatment options, including drug therapies. The endlessly improving healthcare infrastructure, combined with the surge in people's disposable incomes, is expected to make the market grow in the forecast period.

Drivers

Rise in Breast Cancer Cases
As per breastcancer.org, in 2023, it is estimated that nearly 30% of the newly discovered cancer cases in women get diagnosed with breast cancer. Furthermore, triple-negative breast cancer (TNBC) accounts for around 10-15% of all breast cancers. Furthermore, the extensive R&D activities to achieve successful therapeutic for this disease and the increasing number of patients with breast cancer are enhancing the market growth.

Wide Availability of Biosimilar and Generic Anti-Cancer Drugs
The increasing availability of biosimilar and affordable generic anti-cancer drugs in developing nations is anticipated to decrease the burden of cancer care significantly. An estimated cost reduction of around 30% - 40% and extended use of generic drugs is anticipated to decrease overall cancer treatment costs, thus increasing the treatment rate for triple-negative breast cancer. Thus, this boosts market growth.

Recent Developments:

In 2020, Roche collaborated with Kenya's government to improve breast cancer treatment. This campaign was launched to increase women's access to breast cancer prevention and treatment services.
In 2021, sacituzumab govitecan successfully received FDA approval for treating metastatic triple-negative breast cancer patients who had already undergone two or more systemic treatments before, out of which at least one was for metastatic illness.
Key players operating in the global triple-negative breast cancer market include:

Johnson & Johnson Private Limited (U.S.)
Cipla Inc. (U.S.)
Abbott (U.S.)
AbbVie Inc. (U.S.)
Merck KGaA (Germany)
Sun Pharmaceutical Industries Ltd. (India)
Aurobindo Pharma (India)
Lupin (India)
Hikma Pharmaceuticals PLC (U.K.)
Amneal Pharmaceuticals LLC. (U.S.)
Pfizer Inc (U.S.)
Mylan N.V. (U.S.)
Novartis AG (Switzerland)
Bristol-Myers Squibb Company (U.S.)
GSK plc. (U.K.)
Bayer AG (Germany)

To Gain More Insights into the Market Analysis, Browse the Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-triple-negative-breast-cancer-market

GET MORE LINKS:

https://www.zedlike.com/blogs/76335/Medical-Billing-Software-Market-Size-Share-Demand-Future-Growth-Challenges

https://chatterchat.com/read-blog/19676

https://kadeum.com/blogs/52426/Medical-Billing-Software-Market-Size-Share-Demand-Key-Drivers-Development

https://chandrabindu.net/read-blog/2530

https://www.spoke.com/topics/medical-billing-software-market-size-share-trends-demand-growth-forecast-segmentation-and-revenue-outlook-6437f64b0033151fd2001b67

https://www.myidsocial.com/read-blog/6046

https://friendslook.es/read-blog/2223

https://wignar.com/read-blog/14866

https://friendsome.online/read-blog/2073

https://bib.az/read-blog/30814

https://dbmrblogs.wordpress.com/2023/04/13/medical-billing-software-market-industry-overview-size-share-by-company-trends-and-growth-analysis/

https://www.diigo.com/item/note/6nsjl/vgkq?k=11a0eb221e3574961a893426f39faaa5

https://dbmrbuisness.blogspot.com/2023/04/medical-billing-software-market.html

https://databridgemarketresearch.medium.com/medical-billing-software-market-size-share-growth-segment-trends-developing-technologies-and-f71331ebe90

https://www.pearltrees.com/dbmrfeed/item512608073

https://www.onfeetnation.com/profiles/blogs/medical-billing-software-market-size-growth-demands-revenue-top?xg_source=activity

https://www.zupyak.com/p/3595673/t/medical-billing-software-market-industrial-trends-key-manufacturers-regional-analysis-and-opportunities

https://pastelink.net/ndoy1311

https://geto.space/read-blog/106773

https://tannda.net/read-blog/21549

https://www.zedlike.com/blogs/76807/Tularemia-Market-Share-Trends-Key-Drivers-Demand-Opportunities-and-Competitive

https://chatterchat.com/read-blog/19901

https://kadeum.com/blogs/52499/Tularemia-Market-Size-Share-Demand-Key-Drivers-Development-Trends-and

https://chandrabindu.net/read-blog/2575

https://www.spoke.com/topics/tularemia-market-size-share-trends-demand-growth-forecast-segmentation-and-revenue-outlook-64391e4c0433321fe3000098

https://www.myidsocial.com/read-blog/6089

https://www.japanesewomenorg.com/read-blog/1907

https://friendslook.es/read-blog/2253

https://wignar.com/read-blog/15240

https://friendsome.online/read-blog/2114

https://bib.az/read-blog/30954

https://dbmrblogs.wordpress.com/2023/04/14/tularemia-market-size-share-industry-trends-regional-analysis-demand-and-top-players/

https://www.diigo.com/item/note/6nsjl/tekx?k=fcadecf30f9b369084133a880aa15272

https://dbmrbuisness.blogspot.com/2023/04/tularemia-market-industry-share-size.html

https://databridgemarketresearch.medium.com/tularemia-market-size-share-growth-segment-trends-developing-technologies-and-forecast-bc871d4200f0

https://www.pearltrees.com/dbmrfeed/item512781824

https://www.onfeetnation.com/profiles/blogs/tularemia-market-industry-future-growth-latest-technology-new?xg_source=activity

https://www.zupyak.com/p/3597221/t/tularemia-market-size-growth-demands-revenue-top-leading-company-analysis-and-revenue

https://pastelink.net/z7m1dt5m

https://www.databridgemarketresearch.com/reports/global-breast-cancer-liquid-biopsy-market

https://www.databridgemarketresearch.com/reports/global-breast-cancer-drug-market

https://www.databridgemarketresearch.com/reports/global-brca1-and-brca2-genes-market

https://www.databridgemarketresearch.com/reports/global-her2-positive-breast-cancer-treatment-market

https://www.databridgemarketresearch.com/reports/global-breast-cancer-metastatic-market

https://www.databridgemarketresearch.com/reports/global-breast-cancer-diagnostics-market

https://www.databridgemarketresearch.com/reports/global-familial-breast-cancer-treatment-market

https://www.databridgemarketresearch.com/reports/europe-breast-cancer-diagnostics-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:-
Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.